US pharma deal set to boost sales for Japan's Sawai family
Add BT as a preferred sourceTokyo
FOR decades, Japan's Sawai family was content to keep the drug business they founded focused on its home market. Now, they are steering the country's second-biggest maker of generic drugs through its first overseas acquisition in its 88-year history.
Sawai Pharmaceutical Co, which plans to complete its US$1 billion purchase of the generic drug business of Minnesota-based Upsher-Smith Laboratories Inc next month, forecasts sales growth at the US business to reach 13 per cent annually through 2021.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
From post-war hardships to ‘era of national rise’: Vietnam’s family firms face first succession test
‘We’re not a bubble tea brand’: Chagee aims to double Asia-Pacific footprint to 600 stores by 2027
